27780748|t|Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer
27780748|a|Fatigue is the most common toxicity of all grade toxicities with regorafenib, was the second most common toxicity in the CORRECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) study, and is a major reason for early dose modification. The results from a recent randomized study suggested that dexamethasone (DEX) can improve cancer-related fatigue. We retrospectively analyzed the effect of prophylactic use of an oral DEX on fatigue during regorafenib treatment in patients with metastatic colorectal cancer (mCRC). A total of 105 patients who had received regorafenib at our institution from May 2013 to August 2014 were divided into 2 groups according to oral DEX use (2 mg/day; at the physician's discretion). Of the 105 patients, 31 received prophylactic DEX and 74 received regorafenib alone. The time to dose modification was significantly longer in the DEX group than in the no DEX group (15 days vs. 9 days; P = .009). The incidence of fatigue (grade ≥ 1) was significantly lower with DEX than without DEX (25.8% vs. 50.0%; P = .022). Fewer patients experienced a decreased appetite (grade ≥ 1; 3.2% vs. 35.1%; P < .001) and hand-foot skin reaction (HFSR; grade ≥ 3; 3.2% vs. 25.7%, P = .002) with DEX than without DEX. DEX was effective in reducing fatigue during regorafenib treatment, resulting in prolonging the time to dose modification for regorafenib. The decreased incidence of appetite loss and HFSR also suggest that concurrent DEX administration with regorafenib warrants further investigation.
27780748	42	51	Alleviate	T058	UMLS:C1274136
27780748	52	59	Fatigue	T033	UMLS:C0015672
27780748	67	78	Regorafenib	T103	UMLS:C2980094
27780748	107	135	Metastatic Colorectal Cancer	T038	UMLS:C0948380
27780748	136	143	Fatigue	T033	UMLS:C0015672
27780748	163	171	toxicity	T037	UMLS:C0600688
27780748	179	184	grade	T170	UMLS:C0441800
27780748	185	195	toxicities	T037	UMLS:C0600688
27780748	201	212	regorafenib	T103	UMLS:C2980094
27780748	241	249	toxicity	T037	UMLS:C0600688
27780748	257	264	CORRECT	T170	UMLS:C0282574
27780748	266	348	regorafenib monotherapy for previously treated metastatic colorectal cancer) study	T170	UMLS:C0282574
27780748	382	399	dose modification	T062	UMLS:C1707811
27780748	427	443	randomized study	T062	UMLS:C2986910
27780748	459	472	dexamethasone	T103	UMLS:C0011777
27780748	474	477	DEX	T103	UMLS:C0011777
27780748	483	490	improve	T033	UMLS:C0184511
27780748	491	513	cancer-related fatigue	T033	UMLS:C4274302
27780748	518	542	retrospectively analyzed	T062	UMLS:C0035363
27780748	592	599	fatigue	T033	UMLS:C0015672
27780748	607	618	regorafenib	T103	UMLS:C2980094
27780748	646	674	metastatic colorectal cancer	T038	UMLS:C0948380
27780748	676	680	mCRC	T038	UMLS:C0948380
27780748	724	735	regorafenib	T103	UMLS:C2980094
27780748	743	754	institution	T092	UMLS:C2607850
27780748	855	866	physician's	T097	UMLS:C0031831
27780748	926	929	DEX	T103	UMLS:C0011777
27780748	946	957	regorafenib	T103	UMLS:C2980094
27780748	977	994	dose modification	T062	UMLS:C1707811
27780748	1027	1030	DEX	T103	UMLS:C0011777
27780748	1052	1055	DEX	T103	UMLS:C0011777
27780748	1111	1118	fatigue	T033	UMLS:C0015672
27780748	1160	1163	DEX	T103	UMLS:C0011777
27780748	1177	1180	DEX	T103	UMLS:C0011777
27780748	1225	1236	experienced	T038	UMLS:C0596545
27780748	1239	1257	decreased appetite	T033	UMLS:C0232462
27780748	1259	1264	grade	T170	UMLS:C0441800
27780748	1300	1323	hand-foot skin reaction	T038	UMLS:C2721716
27780748	1325	1329	HFSR	T038	UMLS:C2721716
27780748	1331	1336	grade	T170	UMLS:C0441800
27780748	1373	1376	DEX	T103	UMLS:C0011777
27780748	1390	1393	DEX	T103	UMLS:C0011777
27780748	1395	1398	DEX	T103	UMLS:C0011777
27780748	1425	1432	fatigue	T033	UMLS:C0015672
27780748	1440	1451	regorafenib	T103	UMLS:C2980094
27780748	1499	1516	dose modification	T062	UMLS:C1707811
27780748	1521	1532	regorafenib	T103	UMLS:C2980094
27780748	1561	1574	appetite loss	T033	UMLS:C1971624
27780748	1579	1583	HFSR	T038	UMLS:C2721716
27780748	1613	1616	DEX	T103	UMLS:C0011777
27780748	1617	1631	administration	T058	UMLS:C1533734
27780748	1637	1648	regorafenib	T103	UMLS:C2980094
27780748	1666	1679	investigation	T058	UMLS:C0220825